Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-01
2006-08-01
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S252200, C514S252120, C514S254020, C514S254100, C514S256000, C514S317000, C514S321000, C514S323000, C514S326000, C514S329000, C514S330000, C514S331000, C544S295000, C544S376000, C544S377000, C544S335000, C544S382000, C544S383000, C544S368000, C544S379000, C546S196000, C546S197000, C546S209000, C546S214000, C546S223000, C546S225000, C546S236000
Reexamination Certificate
active
07084144
ABSTRACT:
A compound having the general formula (I):wherein: X is N or C; R0is H, a lower alkyl group, a lower O-alkyl group,lower alkyl group, a benzyl group, a phenyl group, a heterocyclic amine group, a cycloalkyl group, a cycloalkyl group substituted with O-alkyl or, a furyl group;R1and R2are, independently, H, an amine group, a lower alkyl group, a lower O-alkyl group, a lower S-alkyl group or a lower N-alkyl group, or R1and R2taken together with the carbon atoms to which they are attached form a five-membered carbocyclic or heterocyclic ring, where the heteroatoms of the heterocyclic ring are one or two oxygen atoms, and/or where any substituent on said carbocyclic or heterocyclic ring is chosen from O, S and N; n is 0,1,2,3 or 4;m is 0 or 1; and pharmaceutically acceptable salts thereof;with the proviso that said compound is not 1-[(4-methoxyphenyl)sulfonyl]piperazine or 1-(1,3-benzodioxol-5-ylsulfonyl)piperazine. The compounds are useful as active ingredients in pharmaceutical compositions and as a medicament for the treatment of erectile dysfunction.
REFERENCES:
patent: 2507408 (1950-05-01), Jacob
patent: 4431813 (1984-02-01), Handte et al.
patent: 6054475 (2000-04-01), Martin et al.
patent: 19825182 (1999-12-01), None
patent: 0 021 592 (1981-01-01), None
patent: 0 304 330 (1989-02-01), None
patent: 0 463 756 (1992-01-01), None
patent: 0638 564 (1994-02-01), None
patent: 0 661 266 (1995-07-01), None
patent: 0 702 555 (1996-03-01), None
patent: 0 330 065 (1999-08-01), None
patent: 1 057 829 (2000-12-01), None
patent: WO 94/28902 (1994-12-01), None
patent: WO 95/04049 (1995-02-01), None
patent: WO 98/49166 (1998-11-01), None
patent: WO 98/54164 (1998-12-01), None
patent: WO 99/06367 (1999-02-01), None
patent: WO 99/26616 (1999-06-01), None
A Screening Concept Based on a Hypothesis Led to the Development of a Putative Cognitive Enhancer That Stimulates Penile Erection, Jpn. J. Pharmacol. 64, 147-153 (1994), Maeda et al.
“Design and Synthesis of Potent and Selective 5,6-Fused Heterocyclic Thrombin Inhibitors,” Celia Dominguez et al., Bioorganic & Medicinal Chemistry Letters, vol. 9 (1999) 925-930, Dominguez et al.
Bernhardt Emily
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
The Jordanian Pharmaceutical MFG & Medical Equipment CO LTD
LandOfFree
Sulfonyl group containing compounds and their use for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonyl group containing compounds and their use for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonyl group containing compounds and their use for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711883